{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T04:38:37Z","timestamp":1720586317813},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,5,13]],"date-time":"2011-05-13T12:00:12Z","timestamp":1305288012000},"page":"305-312","source":"Crossref","is-referenced-by-count":9,"title":["New agents in follicular lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2011.03.006_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.beha.2011.03.006_bib2","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib3","first-page":"1013","article-title":"IMET 3393, (-[1-Methyl-5-bis-(\u03b2-chlor\u00e4thyl)-aminobenzimidazolyl-(2)]-butter s\u00e4urehydrochlorid, ein neues Zytostatikum aus der Reihi der Benzimidazol-Loste","volume":"110","author":"Ozegowski","year":"1971","journal-title":"Zbl Pharm"},{"key":"10.1016\/j.beha.2011.03.006_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.beha.2011.03.006_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.03.006_bib6","first-page":"640a","article-title":"SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action","volume":"102","author":"Leoni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib7","article-title":"In vivo and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells","volume":"45","author":"Leoni","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.beha.2011.03.006_bib8","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2011.03.006_bib9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin\u2019s lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.beha.2011.03.006_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO#19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib13","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in reituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2011.03.006_bib14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter single-agent study","volume":"28","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib15","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin\u2019s lymphoma: results from a large multicenter study","author":"Kahl","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2011.03.006_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CLML.2010.n.079","article-title":"Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.","volume":"10","author":"Cheson","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2011.03.006_bib17","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib18","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma: a phase II multicenter study","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.006_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","article-title":"Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin\u2019s lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel","volume":"10","author":"Cheson","year":"2010","journal-title":"Clin Lymp Leuk Myeloma"},{"key":"10.1016\/j.beha.2011.03.006_bib21","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib24","article-title":"Results of a phase II study of bortezomib in patients with relapsed or refractory indolent lymphoma","author":"Di Bella","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib25","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Part I","key":"10.1016\/j.beha.2011.03.006_bib26","first-page":"446s","article-title":"Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose-finding results of the VERTICAL study","volume":"27","author":"Matous","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib27","unstructured":"Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory folicular lymphoma: the phase 2 VERTICAL study. J Clin Oncol, in press."},{"key":"10.1016\/j.beha.2011.03.006_bib28","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib29","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophages (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2141.2007.06937.x","article-title":"Thalidomide has limited single-agent activity in relapsed or refractory indolen non-Hodgkin\u2019s lymphoma: a phase II study of the CALGB","volume":"140","author":"Smith","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.03.006_bib31","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib32","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1016\/j.beha.2011.03.006_bib33","first-page":"582s","article-title":"Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Fowler","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib34","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"SYK-dependent tonic B-cell receptor signalling is a rational treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib35","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"15s","key":"10.1016\/j.beha.2011.03.006_bib36","first-page":"576s","article-title":"Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.006_bib37","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2011.03.006_bib38","first-page":"436","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD)","volume":"94","author":"Witzig","year":"2009","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.beha.2011.03.006_bib39","first-page":"682","article-title":"Phase I and pharmacokinetic (PK) study of everolimus (RAD001) in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma (NHL)","volume":"114","author":"Ogura","year":"2010","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.beha.2011.03.006_bib40","first-page":"466","article-title":"Clinical activityt in a phase 1 study of CAL-101, as isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with B-cell malignancies","volume":"95","author":"Brown","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.03.006_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia","volume":"113","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib42","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"issue":"18S","key":"10.1016\/j.beha.2011.03.006_bib43","first-page":"362s","article-title":"AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients (pts) with high risk features: preliminary results from an ongoing phase I trial","volume":"24","author":"James","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Part I","key":"10.1016\/j.beha.2011.03.006_bib44","first-page":"434s","article-title":"Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL)","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.006_bib45","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V114.22.1711.1711","article-title":"Phase 1\/2a study of ABT-263 in relapsed or refractory lymphoid malignancies","volume":"114","author":"Wilson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib46","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","article-title":"Phase I dose-finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma","volume":"16","author":"Hwang","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.beha.2011.03.006_bib47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood.V114.22.2718.2718","article-title":"YM155, a novel survivin suppressant, improves the antitumor effect of rituximab and rituximab-containing regimens in diffuse large B cell lymphoma (DLBCL) xenograt mouse models","volume":"114","author":"Nakata","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.006_bib48","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T04:01:07Z","timestamp":1592539267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000338"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}